Information Provided By:
Fly News Breaks for February 25, 2020
Feb 25, 2020 | 07:15 EDT
Wedbush analyst Liana Moussatos raised her price target for United Therapeutics to $243 from $237 after the company announced positive top-line results for the INCREASE Tyvaso/pulmonary hypertension associated with interstitial lung disease trial and an additional 510k clearance by the FDA for Remunity. The analyst has an Outperform rating on the shares.
News For UTHR From the Last 2 Days
There are no results for your query UTHR